Every 10-Q that OrthoPediatrics Corp. (KIDS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KIDS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KIDS filings page.
OrthoPediatrics Corp. reported Q2 2026 net revenue of $70.5 million, up 15% from $61.1 million, with first‑half revenue rising 14% to $129.9 million. Growth was led by trauma and deformity products, where Q2 sales increased 26% to $52.6 million, while scoliosis Q2 revenue declined 9% to $16.9 million. Gross margin improved to 74% from 72% for both the quarter and year‑to‑date.
Q2 operating loss narrowed to $4.1 million from $10.7 million, but higher interest expense turned prior‑year other income into expense, leaving Q2 net loss essentially flat at $7.2 million (EPS $(0.30)). First‑half net loss was $17.9 million, or $(0.75) per share. At June 30, 2026, cash, restricted cash and short‑term investments totaled $47.9 million against total debt of $105.8 million, including a $51.0 million term loan and $50.0 million of 4.75% convertible notes due 2030. Net cash used in operating activities improved to $2.4 million from $14.6 million a year earlier. Management states that existing cash, expected cash flows and an undrawn $20.0 million delayed draw term loan under the Braidwell amendment are expected to support operations for more than 12 months.
OrthoPediatrics Corp. reported first-quarter 2026 net revenue of $59.4 million, up 13% from $52.4 million a year earlier, driven by growth in trauma and deformity, scoliosis and specialty bracing across U.S. and international markets. Gross margin remained strong at 73%.
The company posted a net loss of $10.7 million, similar to the prior-year loss of $10.7 million, with loss per share of $0.45. Operating cash outflow improved to $3.3 million, and cash, restricted cash and short-term investments totaled about $50.9 million. Total debt was $106.7 million, including term loans and a 4.75% convertible note, and OrthoPediatrics added a new $20 million delayed draw term loan facility to expand future liquidity while continuing clinic acquisitions that increased goodwill to $115.2 million.
OrthoPediatrics Corp. reported Q3 2025 results. Net revenue rose to $61,250 thousand from $54,573 thousand, with gross profit of $45,274 thousand. Operating expenses included intangible asset impairment of $2,268 thousand and restructuring of $2,294 thousand, resulting in an operating loss of $9,428 thousand versus $5,566 thousand a year ago. Net loss was $11,773 thousand, or $0.50 per share.
For the nine months, revenue reached $174,743 thousand versus $152,060 thousand, while net loss was $29,545 thousand. Cash was $16,826 thousand and short‑term investments were $40,902 thousand as of September 30, 2025. The company had a term loan of $51,000 thousand and a $50,000 thousand convertible note outstanding. It drew $25,000 thousand from its delayed‑draw term loan on June 27, 2025. Net cash used in operating activities was $15,199 thousand year‑to‑date.
U.S. sales were $48,718 thousand and international sales were $12,532 thousand in Q3. Shares outstanding were 25,077,330 as of October 28, 2025.